ClinicalTrials.gg
CompletedNCT01192191Updated Jan 11, 2017Results posted

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

A Phase 3 interventional study of Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg and Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 35 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
97th of 236
187 · median 101
Started
2010
with 21 others
Phase 3
65 of 276
5 open now
Registered
94th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 97th largest by enrollment of the 236 interventional ones that give a count, is one of 22 that started in 2010, is one of 65 in phase 3, and was the 94th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • GW642444
  • COPD
  • Fluticasone Furoate
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Out patient at least 40 years of age
  • Both genders; females childbearing potencial must be willing to use method
  • A diagnosis of at Screening
  • Subjects with a current or prior history of at least 10 pack-years of cigarett smoking at Screening
  • Post-bronchodilator /FVC ratio of less than 70%
  • Post-bronchodilator FEV1 of less than 80%

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of sthma
  • Respiratory disorders other than
  • Upper or lower respiratory infection, or exacerbation of COPD within 4 weeka prior to Screening
  • Concurrent other disease that would confound study participation or affect subject safety
  • Allergies to study drugs, study drugs' , medications related to study drugs
  • Taking another medication or medication prohibited for use during this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/GW642444 100/25mcg

    Combination inhaled corticosteroid and long-acting beta2-agonist

    Drug: Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg

  • Experimental
    Fluticasone Furoate/GW642444 200/25mcg

    Combination inhaled corticosteroid and long-acting beta2-agonist

    Drug: Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg

Interventions

  • DrugFluticasone Furoate/GW642444 Inhalation Powder 100/25mcg

    Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks

  • DrugFluticasone Furoate/GW642444 Inhalation Powder 200/25mcg

    Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAEs.

    Time frame: From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])

  2. Number of Participants With Any Drug-related AE and Any Drug-related SAE Throughout the Treatment Period

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Relatedness was assessed by the investigator.

    Time frame: From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])

Secondary outcomes

  1. Number of Participants With Pneumonia During the Treatment Period

    Pneumonia is an inflammatory condition of the lung, affecting primarily the microscopic air sacs known as alveoli. All diagnoses of pneumonia (radiographically confirmed or unconfirmed) were reported as an AE or SAE. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the ot

    Time frame: From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])

  2. Number of Participants for the Indicated Hematological Parameters Who Experienced Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)

    Hematological parameters included: Basophils (Baso), Eosinophils (Eosin), Lymphocytes (Lymph), Monocytes (Mono), Total Neutrophils (TN), Hemoglobin (Hemo), Hematocrit (Hmcrt), Platelet Count (PT), Red Blood Cell Count (RBC Count), White Blood Cell Count (WBC Count). Data are reported as the number of participants who had low, normal, and high levels at BL (Week-2) and Week 52/WD.

    Time frame: Baseline (Week -2), and Week 52/Withdrawal (WD)

  3. Number of Participants for the Indicated Clinical Chemistry and Urinalysis Parameters Who Experienced a Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)

    Clinical chemistry and urinalysis parameters included: Albumin, Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Bilirubin (Direct \[BD\], Indirect \[BI\], and Total \[BT\]), Creatine Kinase (CK), Chloride, Carbon Dioxide content/Bicarbonate (CO2/BC), Creatinine, Gamma Glutamyl Transferase (GGT), Glucose, Potassium, Lactate Dehydrogenase (LDH), Sodium, Urine pH, Urine Specific Gravity (USG),Total Protein (TP), Urea/Blood urea nitrogen (BUN), and Uric Acid (UA). Data are reported as the number of participants who had low, normal, and high levels at BL (Week-2) and Week 52/WD.

    Time frame: Baseline (Week -2), and Week 52/Withdrawal (WD

  4. Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline (BL) and Week 52/Withdrawal (WD)

    Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace, 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.

    Time frame: Baseline (Week -2), Week 52/Withdrawal (WD)

  5. Change From Baseline in 24-hour Urinary Cortisol Excretion at Weeks 24 and 52/Withdrawal (WD)

    24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Week 0), Week 24, and Week 52/Withdrawal (WD)

  6. Change From Baseline in Blood Pressure at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD

    Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 52, Week 24/WD, and Week 52/WD

  7. Change From Baseline in Heart Rate (HR) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD

    Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at assessment time points (Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 52, Week 24/WD, Week 52/WD

  8. Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings

    A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Week 12, Week 24, and Week52). Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal findings. Any abnormal ECG, including those that worsen from baseline, and clinically significant as assessed by the investigator were recorded as CS.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52

07

Results

Posted Aug 12, 2013

Participant flow

Participant flow — Overall Study
MilestoneFF/VI 100/25 µgFF/VI 200/25 µg
Started60127
Completed49106
Not completed1121
Withdrew: Adverse event712
Withdrew: Participants reached stopping criteria32
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject16

Outcome measures

PrimaryNumber of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAEs.

Time frame:
From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])
Reported as:
Number · Participants
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period
ParticipantsFF/VI 100/25 µgFF/VI 200/25 µg
Any Non-serious AE3693
Any SAE1023
PrimaryNumber of Participants With Any Drug-related AE and Any Drug-related SAE Throughout the Treatment Period

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Relatedness was assessed by the investigator.

Time frame:
From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])
Reported as:
Number · Participants
Number of Participants With Any Drug-related AE and Any Drug-related SAE Throughout the Treatment Period
ParticipantsFF/VI 100/25 µgFF/VI 200/25 µg
Any AE1230
Any SAE12
SecondaryNumber of Participants With Pneumonia During the Treatment Period

Pneumonia is an inflammatory condition of the lung, affecting primarily the microscopic air sacs known as alveoli. All diagnoses of pneumonia (radiographically confirmed or unconfirmed) were reported as an AE or SAE. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the ot

Time frame:
From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])
Reported as:
Number · Participants
Number of Participants With Pneumonia During the Treatment Period
ParticipantsFF/VI 100/25 µgFF/VI 200/25 µg
Pneumonia recorded as an AE619
Pneumonia recorded as an SAE49
SecondaryNumber of Participants for the Indicated Hematological Parameters Who Experienced Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)

Hematological parameters included: Basophils (Baso), Eosinophils (Eosin), Lymphocytes (Lymph), Monocytes (Mono), Total Neutrophils (TN), Hemoglobin (Hemo), Hematocrit (Hmcrt), Platelet Count (PT), Red Blood Cell Count (RBC Count), White Blood Cell Count (WBC Count). Data are reported as the number of participants who had low, normal, and high levels at BL (Week-2) and Week 52/WD.

Time frame:
Baseline (Week -2), and Week 52/Withdrawal (WD)
Reported as:
Number · Participants
Number of Participants for the Indicated Hematological Parameters Who Experienced Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)
ParticipantsFF/VI 100/25 µgFF/VI 200/25 µg
Baso, High, BL, n=60, 12720
Baso, Normal, BL, n= 60, 12758127
Baso, Low, BL, n= 60, 12700
Baso, High, Week 52/WD, n=56, 12211
Baso, Normal, Week 52/WD, n=56, 12255121
Baso, Low, Week 52/WD n=56, 12200
Eosin, High, BL, n=60, 127515
Eosin, Normal, BL, n=60, 12755112
Eosin, Low, BL, n=60, 12700
Eosin, High, Week 52/WD, n=56, 122511
Eosin, Normal, Week 52/WD, n=56, 12251111
Eosin, Low, Week 52/WD, n=56, 12200
Lymph, High, BL, n=60, 12711
Lymph, Normal, BL, n=60, 12758121
Lymph, Low, BL, n=60, 12715
Lymph, High, Week 52/WD, n=56, 12200
Lymph, Normal, Week 52/WD, n=56, 12251108
Lymph, Low, Week 52/WD, n=56, 122514
Mono, High, BL, n=60, 12798
Mono, Normal, BL, n=60, 12751119
Mono, Low, BL, n=60, 12700
Mono, High, Week 52/WD, n=56, 122714
Mono, Normal, Week 52/WD, n=56, 12249108
Mono, Low, Week 52/WD, n=56, 12200
TN, High, BL, n=60, 12705
TN, Normal, BL, n=60, 12758119
TN, Low, BL, n=60, 12723
TN, High, Week 52/WD, n=56, 122411
TN, Normal, Week 52/WD, n=56, 12252111
TN, Low, Week 52/WD, n=56, 12200
Hemo, High, BL, n=60, 12712
Hemo, Normal, BL, n=60, 12748112
Hemo, Low, BL, n=60, 1271113
Hemo, High, Week 52/WD, n=56, 12200
Hemo, Normal, Week 52/WD, n=56, 12245108
Hemo, Low, Week 52/WD, n=56, 1221114
Hmcrt, High, BL, n=60, 127413
Hmcrt, Normal, BL, n=60, 12750110
Hmcrt, Low, BL, n=60, 12764
Hmcrt, High, Week 52/WD, n=56, 12218
Hmcrt, Normal, Week 52/WD, n=56, 12250106
Hmcrt, Low, Week 52/WD, n=56, 12258
PT, High, BL, n=60, 12710
PT, Normal, BL, n=60, 12757124
PT, Low, BL, n=60, 12723
PT, High, Week 52/WD, n=56, 12224
PT, Normal, Week 52/WD, n=56, 12251116
PT, Low, Week 52/WD, n=56, 12232
RBC Count, High, BL, n=60, 12704
RBC Count, Normal, BL, n=60, 12753111
RBC Count, Low, BL, n=60, 127712
RBC Count, High, Week 52/WD, n=56, 12202
RBC Count, Normal, Week 52/WD, n=56, 12247107
RBC Count, Low, Week 52/WD, n=56, 122913
WBC Count, High, BL, n=60, 12726
WBC Count, Normal, BL, n=60, 12757119
WBC Count, Low, BL, n=60, 12712
WBC Count, High, Week 52/WD, n=56, 12234
WBC Count, Normal, Week 52/WD, n=56, 12252116
WBC Count, Low, Week 52/WD, n=56, 12212
SecondaryNumber of Participants for the Indicated Clinical Chemistry and Urinalysis Parameters Who Experienced a Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)

Clinical chemistry and urinalysis parameters included: Albumin, Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Bilirubin (Direct \[BD\], Indirect \[BI\], and Total \[BT\]), Creatine Kinase (CK), Chloride, Carbon Dioxide content/Bicarbonate (CO2/BC), Creatinine, Gamma Glutamyl Transferase (GGT), Glucose, Potassium, Lactate Dehydrogenase (LDH), Sodium, Urine pH, Urine Specific Gravity (USG),Total Protein (TP), Urea/Blood urea nitrogen (BUN), and Uric Acid (UA). Data are reported as the number of participants who had low, normal, and high levels at BL (Week-2) and Week 52/WD.

Time frame:
Baseline (Week -2), and Week 52/Withdrawal (WD
Reported as:
Number · Participants
Number of Participants for the Indicated Clinical Chemistry and Urinalysis Parameters Who Experienced a Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)
ParticipantsFF/VI 100/25 µgFF/VI 200/25 µg
Albumin, High, BL, n=60, 12702
Albumin, Normal, BL, n=60, 12756112
Albumin, Low, BL, n=60, 127413
Albumin, High, Week 52/WD, n=56, 12201
Albumin, Normal, Week 52/WD, n=56, 1224999
Albumin, Low, Week 52/WD, n=56, 122722
AP, High, BL, n=60, 127410
AP, Normal, BL, n=60, 12756117
AP, Low, BL, n=60, 12700
AP, High, Week 52/WD, n=56, 12256
AP, Normal, Week 52/WD, n=56, 12251116
AP, Low, Week 52/WD, n=56, 12200
ALT, High, BL, n=60, 12749
ALT, Normal, BL, n=60, 12756117
ALT, Low, BL, n=60, 12701
ALT, High, Week 52/WD, n=56, 12246
ALT, Normal, Week 52/WD, n=56, 12252116
ALT, Low, Week 52/WD, n=56, 12200
AST, High, BL, n=60, 127511
AST, Normal, BL, n=60, 12755116
AST, Low, BL, n=60, 12700
AST, High, Week 52/WD, n=56, 12235
AST, Normal, Week 52/WD, n=56, 12253117
AST, Low, Week 52/WD, n=56, 12200
BD, High, BL, n=60, 12774
BD, Normal, BL, n=60, 12753123
BD, Low, BL, n=60, 12700
BD, High, Week 52/WD, n=56, 12234
BD, Normal, Week 52/WD, n=56, 12253118
BD, Low, Week 52/WD, n=56, 12200
BI, High, BL, n=60, 12741
BI, Normal, BL, n=60, 12756126
BI, Low, BL, n=60, 12700
BI, High, Week 52/WD, n=56, 12232
BI, Normal, Week 52/WD, n=56, 12253120
BI, Low, Week 52/WD, n=56, 12200
BT, High, BL, n=60, 12765
BT, Normal, BL, n=60, 12754122
BT, Low, BL, n=60, 12700
BT, High, Week 52/WD, n=56, 12263
BT, Normal, Week 52/WD, n=56, 12250119
BT, Low, Week 52/WD, n=56, 12200
CK, High, BL, n=60, 127610
CK, Normal, BL, n=60, 12748102
CK, Low, BL, n=60, 127615
CK, High, Week 52/WD, n=56, 12277
CK, Normal, Week 52/WD, n=56, 1224492
CK, Low, Week 52/WD, n=56, 122523
Chloride, High, BL, n=60, 12710
Chloride, Normal, BL, n=60, 12758124
Chloride, Low, BL, n=60, 12713
Chloride, High, Week 52/WD, n=56, 12226
Chloride, Normal, Week 52/WD, n=56, 12254115
Chloride, Low, Week 52/WD, n=56, 12201
CO2/BC, High, BL, n=60, 12701
CO2/BC, Normal, BL, n=60, 12757120
CO2/BC, Low, BL, n=60, 12736
CO2/BC, High, Week 52/WD, n=56, 12101
CO2/BC, Normal, Week 52/WD, n=56, 12148116
CO2/BC, Low, Week 52/WD, n=56, 12184
Creatinine, High, BL, n=60, 12789
Creatinine, Normal, BL, n=60, 12750115
Creatinine, Low, BL, n=60, 12723
Creatinine, High, Week 52/WD, n=56, 122610
Creatinine, Normal, Week 52/WD, n=56, 12247108
Creatinine, Low, Week 52/WD, n=56, 12234
GGT, High, BL, n=60, 127925
GGT, Normal, BL, n=60, 12751102
GGT, Low, BL, n=60, 12700
GGT, High, Week 52/WD, n=56, 1221019
GGT, Normal, Week 52/WD, n=56, 12246103
GGT, Low, Week 52/WD, n=56, 12200
Glucose, High, BL, n=60, 1271658
Glucose, Normal, BL, n=60, 1274365
Glucose, Low, BL, n=60, 12714
Glucose, High, Week 52/WD, n=56, 1222656
Glucose, Normal, Week 52/WD, n=56, 1223065
Glucose, Low, Week 52/WD, n=56, 12201
Potassium, High, BL, n=60, 12725
Potassium, Normal, BL, n=60, 12754116
Potassium, Low, BL, n=60, 12746
Potassium, High, Week 52/WD, n=56, 12215
Potassium, Normal, Week 52/WD, n=56, 12253111
Potassium, Low, Week 52/WD, n=56, 12226
LDH, High, BL, n=60, 12719
LDH, Normal, BL, n=60, 12759116
LDH, Low, BL, n=60, 12702
LDH, High, Week 52/WD, n=56, 122410
LDH, Normal, Week 52/WD, n=56, 12252111
LDH, Low, Week 52/WD, n=56, 12201
Sodium, High, BL, n=60, 12700
Sodium, Normal, BL, n=60, 12758125
Sodium, Low, BL, n=60, 12722
Sodium, High, Week 52/WD, n=56, 12200
Sodium, Normal, Week 52/WD, n=56, 12255120
Sodium, Low, Week 52/WD, n=56, 12212
Urine pH, High, BL, n=60, 12701
Urine pH, Normal, BL, n=60, 12760126
Urine pH, Low, BL, n=60, 12700
Urine pH, High, Week 52/WD, n=56, 12200
Urine pH, Normal, Week 52/WD, n=56, 12256122
Urine pH, Low, Week 52/WD, n=56, 12200
USG, High, BL, n=60, 12721
USG, Normal, BL, n=60, 12758126
USG, Low, BL, n=60, 12700
USG, High, Week 52/WD, n=56, 12220
USG, Normal, Week 52/WD, n=56, 12254122
USG, Low, Week 52/WD, n=56, 12200
TP, High, BL, n=60, 12713
TP, Normal, BL, n=60, 12755118
TP, Low, BL, n=60, 12746
TP, High, Week 52/WD, n=56, 12213
TP, Normal, Week 52/WD, n=56, 12249102
TP, Low, Week 52/WD, n=56, 122617
Urea/BUN, High, BL, n=60, 127513
Urea/BUN, Normal, BL, n=60, 12754114
Urea/BUN, Low, BL, n=60, 12710
Urea/BUN, High, Week 52/WD, n=56, 12285
Urea/BUN, Normal, Week 52/WD, n=56, 12248116
Urea/BUN, Low, Week 52/WD, n=56, 12201
UA, High, BL, n=60, 1271322
UA, Normal, BL, n=60, 12746102
UA, Low, BL, n=60, 12713
UA, High, Week 52/WD, n=56, 1221323
UA, Normal, Week 52/WD, n=56, 1224292
UA, Low, Week 52/WD, n=56, 12217
SecondaryNumber of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline (BL) and Week 52/Withdrawal (WD)

Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace, 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.

Time frame:
Baseline (Week -2), Week 52/Withdrawal (WD)
Reported as:
Number · Participants
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline (BL) and Week 52/Withdrawal (WD)
ParticipantsFF/VI 100/25 µgFF/VI 200/25 µg
UOB, Neg, BL, n=60, 12754112
UOB, Trace, BL, n=60, 12746
UOB, 1+, BL, n=60, 12715
UOB, 2+, BL, n=60, 12712
UOB, 3+, BL, n=60, 12702
UOB, Neg, Week 52/WD, n=56, 12251103
UOB, Trace, Week 52/WD, n=56, 122311
UOB, 1+, Week 52/WD, n=56, 12215
UOB, 2+, Week 52/WD, n=56, 12211
UOB, 3+, Week 52/WD, n=56, 12202
UG, Neg, BL, n=60, 12754117
UG, Trace, BL, n=60, 12734
UG, 1+, BL, n=60, 12721
UG, 2+, BL, n=60, 12712
UG, 3+, BL, n=60, 12703
UG, Neg, Week 52/WD, n=56, 12249109
UG, Trace, Week 52/WD, n=56, 12225
UG, 1+, Week 52/WD, n=56, 12231
UG, 2+, Week 52/WD, n=56, 12225
UG, 3+, Week 52/WD, n=56, 12202
UK, Neg, BL, n=60, 12760127
UK, Trace, BL, n=60, 12700
UK, 1+, BL, n=60, 12700
UK, 2+, BL, n=60, 12700
UK, 3+, BL, n=60, 12700
UK, Neg, Week 52/WD, n=56, 12256122
UK, Trace, Week 52/WD, n=56, 12200
UK, 1+, Week 52/WD, n=56, 12200
UK, 2+, Week 52/WD, n=56, 12200
UK, 3+, Week 52/WD, n=56, 12200
UP, Neg, BL, n=60, 12748103
UP, Trace, BL, n=60, 1271013
UP, 1+, BL, n=60, 12728
UP, 2+, BL, n=60, 12703
UP, 3+, BL, n=60, 12700
UP, Neg, Week 52/WD, n=56, 1224192
UP, Trace, Week 52/WD, n=56, 1221020
UP, 1+, Week 52/WD, n=56, 12248
UP, 2+, Week 52/WD, n=56, 12212
UP, 3+, Week 52/WD, n=56, 12200
UWBC, Neg, BL, n=60, 12758120
UWBC, Trace, BL, n=60, 12700
UWBC, 1+, BL, n=60, 12716
UWBC, 2+, BL, n=60, 12701
UWBC, 3+, BL, n=60, 12710
UWBC, Neg, Week 52/WD, n=56, 12255108
UWBC, Trace, Week 52/WD, n=56, 12200
UWBC, 1+, Week 52/WD, n=56, 122111
UWBC, 2+, Week 52/WD, n=56, 12203
UWBC, 3+, Week 52/WD, n=56, 12200
SecondaryChange From Baseline in 24-hour Urinary Cortisol Excretion at Weeks 24 and 52/Withdrawal (WD)

24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Week 0), Week 24, and Week 52/Withdrawal (WD)
Reported as:
Geometric mean · Nanomoles (nmol)/24 hours
Change From Baseline in 24-hour Urinary Cortisol Excretion at Weeks 24 and 52/Withdrawal (WD)
Nanomoles (nmol)/24 hoursFF/VI 100/25 µgFF/VI 200/25 µg
Week 24, n=25, 431.0627 ± 76.1350.8160 ± 55.926
Week 52/WD, n=24, 410.8862 ± 37.0780.8593 ± 52.770
SecondaryChange From Baseline in Blood Pressure at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD

Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 52, Week 24/WD, and Week 52/WD
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Blood Pressure at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD
Millimeters of Mercury (mmHg)FF/VI 100/25 µgFF/VI 200/25 µg
SBP, Week 4, n=58, 1244.3 ± 12.051.2 ± 12.47
SPB, Week 8, n=58, 1232.5 ± 11.970.4 ± 13.33
SPB, Week 12, n=57, 1192.7 ± 14.881.2 ± 14.00
SBP, Week 16, n=57, 1161.2 ± 12.940.9 ± 14.18
SBP, Week 24, n=53, 115-0.3 ± 13.20-1.3 ± 14.63
SBP, Week 32, n=53, 112-1.8 ± 12.77-5.0 ± 14.76
SBP, Week 40, n=50, 107-3.0 ± 13.65-3.9 ± 14.06
SBP, Week 52, n=49, 1063.7 ± 15.430.7 ± 15.16
SBP, Week 24/WD, n=56, 125-0.9 ± 13.73-1.1 ± 14.48
SBP, Week 52/WD, n=56, 1232.4 ± 15.721.1 ± 15.82
DBP, Week 4, n=58, 1243.3 ± 9.070.9 ± 10.13
DBP, Week 8, n=58, 1230.1 ± 8.481.0 ± 9.55
DBP, Week 12, n=57, 1190.7 ± 8.090.8 ± 10.76
DBP, Week 16, n=57, 1160.4 ± 9.690.7 ± 10.76
DBP, Week 24, n=53, 1150.3 ± 9.30-1.1 ± 11.71
DBP, Week 32, n=53, 112-1.6 ± 8.50-1.6 ± 11.23
DBP, Week 40, n=50, 107-1.6 ± 8.89-0.3 ± 11.08
DBP, Week 52, n=49, 1061.2 ± 12.430.8 ± 10.77
DBP, Week 24/WD, n=56, 1250.2 ± 9.34-1.2 ± 11.42
DBP, Week 52/WD, n=56, 1230.8 ± 11.970.7 ± 11.29
SecondaryChange From Baseline in Heart Rate (HR) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD

Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at assessment time points (Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 52, Week 24/WD, Week 52/WD
Reported as:
Mean · Beats/Minute
Change From Baseline in Heart Rate (HR) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD
Beats/MinuteFF/VI 100/25 µgFF/VI 200/25 µg
HR, Week 4, n=58, 1240.2 ± 9.84-0.3 ± 11.04
HR, Week 8, n=58, 123-0.2 ± 11.410.3 ± 12.06
HR, Week 12, n=57, 119-1.6 ± 9.37-0.1 ± 11.27
HR, Week 16, n=57, 1160.7 ± 9.501.5 ± 12.58
HR, Week 24, n=53, 115-0.7 ± 10.69-1.1 ± 11.53
HR, Week 32, n=53, 112-0.5 ± 9.230.1 ± 10.30
HR, Week 40, n=50, 1071.7 ± 9.66-0.3 ± 11.59
HR, Week 52, n=49, 1061.9 ± 9.321.1 ± 12.12
HR, Week 24/WD, n=56, 125-1.1 ± 11.03-0.7 ± 11.43
HR, Week 52/WD, n=56, 1231.8 ± 10.622.0 ± 12.71
SecondaryNumber of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings

A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Week 12, Week 24, and Week52). Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal findings. Any abnormal ECG, including those that worsen from baseline, and clinically significant as assessed by the investigator were recorded as CS.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52
Reported as:
Number · Participants
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
ParticipantsFF/VI 100/25 µgFF/VI 200/25 µg
BL, CS, n=60, 12700
BL, NCS, n=60, 1271943
Week 12, CS, n=57, 11901
Week 12, NCS, n=57, 1191737
Week 24, CS, n=54, 11500
Week 24, NCS, n=54, 1151733
Week 52, CS, n=49, 10611
Week 52, NCS, n=49, 1061435

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF/VI 100/25 µg—10/60 (16.7%)36/60 (60%)
FF/VI 200/25 µg—23/127 (18.1%)93/127 (73.2%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventFF/VI 100/25 µgFF/VI 200/25 µg
PneumoniaInfections and infestations3/608/127
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/603/127
BronchopneumoniaInfections and infestations1/600/127
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/601/127
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/600/127
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/600/127
Inguinal herniaGastrointestinal disorders1/600/127
Ventricular tachycardiaCardiac disorders1/600/127
Age-related macular degenerationEye disorders1/600/127
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/602/127
Most frequent other events
Most frequent other events
EventFF/VI 100/25 µgFF/VI 200/25 µg
NasopharyngitisInfections and infestations18/6054/127
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders8/6012/127
Back painMusculoskeletal and connective tissue disorders4/6013/127
DysphoniaRespiratory, thoracic and mediastinal disorders6/608/127
BronchitisInfections and infestations5/608/127
Oral candidiasisInfections and infestations0/6010/127
PharyngitisInfections and infestations4/607/127
EczemaSkin and subcutaneous tissue disorders4/606/127
PneumoniaInfections and infestations1/608/127
ConstipationGastrointestinal disorders3/604/127

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF/VI 100/25 µgFF/VI 200/25 µgTotal
Mean69.5 ± 7.6671.0 ± 7.3970.5 ± 7.49
Gender
Gender(Participants)FF/VI 100/25 µgFF/VI 200/25 µgTotal
Female21113
Male58116174
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FF/VI 100/25 µgFF/VI 200/25 µgTotal
Asian - Japanese Heritage60127187
08

Study locations

35 sites
  • GSK Investigational Site
    Fukuoka, 811-2201, Japan
  • GSK Investigational Site
    Fukuoka, 819-8555, Japan
  • GSK Investigational Site
    Fukushima, 964-0871, Japan
  • GSK Investigational Site
    Gunma, 371-0048, Japan
  • GSK Investigational Site
    Hiroshima, 732-0057, Japan
  • GSK Investigational Site
    Hokkaido, 001-0901, Japan
  • GSK Investigational Site
    Hokkaido, 064-0915, Japan
  • GSK Investigational Site
    Hokkaido, 070-8644, Japan
  • GSK Investigational Site
    Hyogo, 651-0073, Japan
  • GSK Investigational Site
    Ibaraki, 300-0053, Japan
  • GSK Investigational Site
    Ibaraki, 310-0015, Japan
  • GSK Investigational Site
    Ishikawa, 920-8610, Japan
  • GSK Investigational Site
    Kagawa, 760-0073, Japan
  • GSK Investigational Site
    Kagawa, 763-8502, Japan
  • GSK Investigational Site
    Kanagawa, 239-0821, Japan
  • GSK Investigational Site
    Kyoto, 601-1495, Japan
  • GSK Investigational Site
    Kyoto, 615-8087, Japan
  • GSK Investigational Site
    Miyagi, 981-8563, Japan
  • GSK Investigational Site
    Miyagi, 984-8560, Japan
  • GSK Investigational Site
    Nagano, 390-0303, Japan
  • GSK Investigational Site
    Nagano, 390-0832, Japan
  • GSK Investigational Site
    Nagano, 390-8601, Japan
  • GSK Investigational Site
    Nagano, 391-0011, Japan
  • GSK Investigational Site
    Oita, 870-0921, Japan
  • GSK Investigational Site
    Oita, 876-0047, Japan
  • GSK Investigational Site
    Okayama, 701-0304, Japan
  • GSK Investigational Site
    Osaka, 530-0012, Japan
  • GSK Investigational Site
    Osaka, 545-8586, Japan
  • GSK Investigational Site
    Osaka, 576-0016, Japan
  • GSK Investigational Site
    Osaka, 589-0022, Japan
  • GSK Investigational Site
    Tokyo, 185-0014, Japan
  • GSK Investigational Site
    Tokyo, 187-0024, Japan
  • GSK Investigational Site
    Toyama, 930-0194, Japan
  • GSK Investigational Site
    Wakayama, 641-8510, Japan
  • GSK Investigational Site
    Yamanashi, 400-0031, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 7 months after primary completion. A results delay was requested in Mar 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Aug 31, 2010
Start
Aug 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results delay requested
Mar 28, 2013
Results first posted
Aug 12, 2013
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01192191
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 31, 2010
Start date
Aug 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Aug 12, 2013
Last update
Jan 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion